Global Sepsis Diagnostics Market (2021-2026) Growth, Trends, COVID-19 Impact, and Forecast –


DUBLIN – (COMMERCIAL THREAD) – The report “Sepsis Diagnostics Market – Growth, Trends, Impact of COVID-19 and Forecast (2021 – 2026)” has been added to offer.

The sepsis diagnostics market was valued at USD 550 million in 2020 and is expected to reach USD 975 million in 2026 registering a CAGR of 9.8% during the forecast period.

Companies mentioned

  • Abbott Laboratories Inc.

  • Axis-Shield Diagnostics Ltd.

  • Becton, Dickinson and company

  • BioMérieux SA

  • Bruker Company

  • Cube Dx GmbH

  • Danaher Company

  • EKF diagnosis

  • F. Hoffmann-LA Roche SA

  • Immunexpress Inc.

  • Diasorin

  • Response Biomedical Corp.

  • Sysmex Company

  • T2 Biosystems, Inc.

  • Thermo Fisher Scientific

Key market trends

The molecular diagnostics segment, by technology, is expected to experience the fastest growth during the forecast period.

According to the Canadian Medical Association, as of December 2020, the most common complications associated with COVID-19 were pneumonia, respiratory failure, kidney failure, and sepsis or systemic inflammation, according to other studies. The absolute risk of sepsis in someone with COVID-19 has been estimated to be around 10.4%. Researchers are trying to develop a molecular diagnostic capable of detecting COVID-19 and sepsis, as well as distinguishing between the two. In November 2020, the Hellenic Institute for the Study of Sepsis and, in part by Sanmina Corporation, funded a study and developed a new optical biosensor for the early diagnosis of sepsis and severe COVID-19. These developments are expected to have a positive impact on the growth of the market.

Sepsis affects large patient populations in hospitals and is the sixth reason for hospitalization. The rapid and accurate profiling of pathogens causing infection remains a significant challenge in modern healthcare. In addition, the identification of the responsible pathogen is essential in choosing an appropriate antibiotic therapy for treatment. These requirements make molecular diagnostics (MDx) an attractive approach to consider for the diagnosis of sepsis. Molecular diagnostics have attracted several multinational companies and institutions, due to their ease of feasibility and the precision of their detection methods. Analysis of blood cultures for rapid and accurate profiling of infections has been the gold standard for the molecular diagnostic method.

However, the cost of molecular diagnostics has remained very high, compared to conventional procedures, which limits the growth of its market. Several companies are investing in point-of-care molecular diagnostics for the early diagnosis of bacterial and viral pathogens and better patient management. For example, in April 2019, GenMark Diagnostics, Inc. received FDA clearance for its new panel test, developed to detect gram-negative bacteria causing sepsis. The well-established healthcare infrastructure with strong adoption of advanced diagnostic technologies and growing awareness of early disease diagnosis are expected to drive the market growth.

North America is expected to have the largest share of the market

COVID-19 has increased the overall risk of sepsis among the world’s population. The Global Sepsis Alliance has said COVID-19 could cause sepsis, eliciting an overwhelming and potentially fatal physiological response to infection that can lead to organ damage and death. In the United States, one in three COVID-19 patients who die in a hospital die of sepsis. Due to this high susceptibility to the disease in this region, the market is expected to grow in the future.

North America holds a significant share of the sepsis diagnostics market and is expected to show a similar trend during the forecast period without significant fluctuations. According to statistics from the CDC in 2018, sepsis affects more than one million Americans each year and causes 15 to 30% of deaths in the United States. In addition, the number of sepsis cases is increasing every year in the country due to factors such as the increase in the geriatric population, infections that cannot be cured by antibiotics and the higher risks of disease in people who have had a transplant. organ.

The National Institutes of Health supports numerous studies focused on sepsis, which evaluate various potential treatments for the disease. The CDC has launched “Get Ahead of Sepsis,” which is an educational initiative to protect Americans from the effects of sepsis. This initiative calls on healthcare professionals to educate patients, prevent infections, identify and diagnose sepsis at an early stage, and begin treatment for sepsis early. Emerging technologies coupled with a better understanding of the immature and developing responses of the neonatal immune system to early infection provide an opportunity to develop essential biomarkers to improve early identification in this high risk population.

Main topics covered:





4.1 Market overview

4.2 Market drivers

4.2.1 Growing burden of sepsis

4.2.2 Growing incidence of nosocomial infections

4.2.3 Increase in the number of sepsis procedures and increase in funding for research activities related to sepsis

4.3 Market restrictions

4.3.1 High cost of automated diagnostic instruments

4.3.2 Lack of well-established reimbursement policies for sepsis

4.4 Porter’s five forces analysis


5.1 By technology

5.2 By product

5.3 By diagnostic method

5.4 By pathogen

5.5 Geography


6.1 Company profiles


For more information on this report, visit


Comments are closed.